TUCSON, Ariz., July 6, 2023 — Critical Path Institute (C-Path) and the Center for Health + Technology (CHeT) at University of Rochester today announced the release of two seminal publications about digital health technologies for Parkinson’s. These technologies, such as smartphones and wearable sensors, offer an opportunity for objective, frequent and remote assessment of people with Parkinson’s.Continue reading→

TUCSON, Ariz., June 28, 2023 — Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today its first two research grants supporting academic scientists in advancing novel compounds through the drug development process. Launched in June 2022, TRxA is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics, from the lab to patientsContinue reading→

TUCSON, Ariz., June 20, 2023 — Critical Path Institute (C-Path), an independent nonprofit organization, today announced it is providing access to the Critical Path for Parkinson’s (CPP) Integrated Parkinson’s Database to external qualified researchers.Continue reading→

Safety biomarkers aim to provide an additional tool for detecting acute drug-induced pancreatic injury (DIPI) in phase 1 clinical trialsContinue reading→

TUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies to accelerate drug development, Critical Path Institute (C-Path) today shared a year-in-review of its European-focused activities to advance global regulatory science.Continue reading→

TUCSON, Ariz., March 29, 2023 — Critical Path Institute (C-Path) announced today the appointment of three accomplished leaders to key executive roles within the organization. Cheryl D. Coon, Ph.D., joins C-Path as the Vice President for the Clinical Outcome Assessment (COA) Program. Shu Chin Ma, Ph.D., M.Sc., M.Phil., EMBA, has been named Vice President of Model-Informed Drug Development (MIDD) and the Quantitative Medicine (QuantMed) Program. Alexandre Bétourné, Ph.D., Pharm.D., has been promoted to Executive Director of the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP).Continue reading→

TUCSON, Ariz., Jan. 25, 2023 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has issued a letter of support for the Duchenne Regulatory Science Consortium’s (D-RSC) Model-based Clinical Trial Simulation Platform for Duchenne Muscular Dystrophy (DMD).Continue reading→

TUCSON, Ariz., Dec. 20, 2022 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has issued a letter of support for the Critical Path for Parkinson’s (CPP) Consortium’s Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease (PD).Continue reading→

The iBox Scoring System is available for use in kidney transplant clinical trials as a novel secondary endpoint prognostic for allograft loss.Continue reading→

TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced a data sharing agreement to incorporate rare disease patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading→